Clinical trial
Oral Switch Versus Standard Intravenous Antibiotics in Children and Adolescents Who Are Immunocompromised and/or a Central Venous Catheter and Uncomplicated Bloodstream Infections: a Nationwide Randomised Controlled Non-inferiority Trial
NCT07923266 is registered in ClinicalTrials.gov with Copenhagen University Hospital, Rigshospitalet as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Oral Switch Versus Standard Intravenous Antibiotics in Children and Adolescents Who Are Immunocompromised and/or a Central Venous Catheter and Uncomplicated Bloodstream Infections: a Nationwide Randomised Controlled Non-inferiority Trial
- Lead sponsor
- Copenhagen University Hospital, Rigshospitalet
- Phase
- Phase 4
- Overall status
- Recruiting
- Start date
- November 9, 2026
- Completion date
- February 1, 2030
- Enrollment
- 114 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
bacteremia sepsis, bloodstream infection, bloodstream infection due to central venous catheter, immunocompromised patients
Arms
As registered; 2 arms.
-
Early Oral Switch
Early Oral Switch
-
Standard Intravenous Therapy
Standard Intravenous Therapy
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Recurrence of blood stream infection
Number of patients who experience growth of the same bacteria as in the index blood stream infection in a subsequent blood culture during the follow-up period.
Lead sponsor's other trials
Copenhagen University Hospital, Rigshospitalet, most recent start first.
+1,043 more trials See the organization page
Similar trials
Same condition (Bacteremia) and phase, most recent start first.
+29 more trials See the condition page